BAM
TERN

Bellevue Asset Management’s Terns Pharmaceuticals TERN Stock Holding History

Bellevue Asset Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-43
Closed -$1.74K – 482
2025
Q4 		$1.74K Buy
+43
New +$994 ﹤0.01% 455

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Bellevue Asset Management's TERN Position: Q1 2026 in Review

Bellevue Asset Management sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 43 shares — an estimated $1.74K sold.

Bellevue Asset Management first reported a position in TERN in Q4 2025 and held it in 1 quarter. The position peaked at $1.74K in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Bellevue Asset Management reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bellevue Asset Management sold 43 Terns Pharmaceuticals shares in Q1 2026, an estimated $1.74K.
  • Bellevue Asset Management first reported a position in Terns Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Bellevue Asset Management's Terns Pharmaceuticals position peaked at $1.74K in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Bellevue Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.